Overview

Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
An open label, randomized, three-period, three-treatment, six-sequence, crossover, balanced, single dose, dose proportionality study.
Phase:
Phase 1
Details
Lead Sponsor:
Seasons Biotechnology (Taizhou) Co., Ltd.
Treatments:
Vortioxetine